However, the demonstration in the present study of overexpression of GSTPi in α-SMA-positive CAF is new and raises the possibility that their presence in tumour microenvironment could be a contributing factor that may act alone or in synergy with other factors for the development of chemoresistance in patients with GSTPi-negative breast cancer cells. This evidence concerns the gene ACTA1 and breast carcinoma.